Completed

Monitoring Safety and Effectiveness of Trajenta (Linagliptin) in Korean Patients with Type 2 Diabetes

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to monitor the safety and effectiveness of Trajenta (Linagliptin) in Korean patients with Type 2 Diabetes by observing the percentage of patients who experience any adverse events after taking at least one dose of the medication.

What is being collected

Drug Data

Collected from today forward - Prospective
Drug
Who is being recruted

Diabetes Mellitus+3

+ Endocrine System Diseases

+ Metabolic Diseases

Over 19 Years
See all eligibility criteria
How is the trial designed

Other

Utilizing specific methods not covered by standard models in order to address unique research questions.
Observational
Study Start: November 2012
See protocol details

Summary

Principal SponsorBoehringer Ingelheim
Last updated: January 11, 2019
Sourced from a government-validated database.Claim as a partner

Study start date: November 16, 2012

Actual date on which the first participant was enrolled.

Study Design: Post Marketing study- Observational study

NCT01707147
Principal SponsorBoehringer Ingelheim
Last updated: January 11, 2019
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

3219 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other

Some studies use unique or mixed approaches that don't fit standard categories. These may include innovative observational methods or studies tailored to specific research questions.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 19 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Diabetes MellitusEndocrine System DiseasesMetabolic DiseasesNutritional and Metabolic DiseasesGlucose Metabolism DisordersDiabetes Mellitus, Type 2

Criteria

Inclusion criteria: Patients who have been started on Trajenta in accordance with the approved label in Korea Patients who have signed on the data release consent form Exclusion criteria: Patients with previous exposure to Trajenta and current participation in clinical trials

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Multiple Locations, South KoreaOpen in Google Maps
CompletedOne Study Center